255 related articles for article (PubMed ID: 19955744)
1. Treatment of recurrent platinum-resistant ovarian cancer with pegylated liposomal doxorubicin--an evaluation of the therapeutic index with special emphasis on cardiac toxicity.
Steppan I; Reimer D; Sevelda U; Ulmer H; Marth C; Zeimet AG
Chemotherapy; 2009; 55(6):391-8. PubMed ID: 19955744
[TBL] [Abstract][Full Text] [Related]
2. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
Tanyi JL; Smith JA; Ramos L; Parker CL; Munsell MF; Wolf JK
Gynecol Oncol; 2009 Aug; 114(2):219-24. PubMed ID: 19446868
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.
Strauss HG; Hemsen A; Karbe I; Lautenschläger C; Persing M; Thomssen C
Anticancer Drugs; 2008 Jun; 19(5):541-5. PubMed ID: 18418221
[TBL] [Abstract][Full Text] [Related]
4. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
Oskay-Oezcelik G; Koensgen D; Hindenburg HJ; Klare P; Schmalfeldt B; Lichtenegger W; Chekerov R; Al-Batran SE; Neumann U; Sehouli J;
Anticancer Res; 2008; 28(2B):1329-34. PubMed ID: 18505074
[TBL] [Abstract][Full Text] [Related]
5. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
Sehouli J; Camara O; Schmidt M; Mahner S; Seipelt G; Otremba B; Schmalfeldt B; Tesch H; Lorenz-Schlüter C; Oskay-Ozcelik G;
Cancer Chemother Pharmacol; 2009 Aug; 64(3):585-91. PubMed ID: 19156414
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.
Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):369-72. PubMed ID: 10985896
[TBL] [Abstract][Full Text] [Related]
7. Elevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin.
Gordinier ME; Dizon DS; Fleming EL; Weitzen S; Schwartz J; Parker LP; Granai CO
Gynecol Oncol; 2006 Oct; 103(1):72-4. PubMed ID: 16494932
[TBL] [Abstract][Full Text] [Related]
8. Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up.
; Chou HH; Wang KL; Chen CA; Wei LH; Lai CH; Hsieh CY; Yang YC; Twu NF; Chang TC; Yen MS
Gynecol Oncol; 2006 Jun; 101(3):423-8. PubMed ID: 16325239
[TBL] [Abstract][Full Text] [Related]
9. Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction.
Li Y; Finkel KW; Hu W; Fu S; Liu J; Coleman R; Kavanagh JJ
Gynecol Oncol; 2007 Aug; 106(2):375-80. PubMed ID: 17512575
[TBL] [Abstract][Full Text] [Related]
10. Recurrent ovarian cancer: treatment with pegylated liposomal doxorubicin; a Westmead Cancer Care Centre experience.
Dear RF; Gao B; Harnett P
Asia Pac J Clin Oncol; 2010 Mar; 6(1):66-73. PubMed ID: 20398040
[TBL] [Abstract][Full Text] [Related]
11. Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients.
Gorumlu G; Kucukzeybek Y; Kemal-Gul M; Karaca B; Cosan-Terek M; Karabulut B; Sanli UA; Akman L; Ozsaran A; Dikmen Y; Uslu R
J BUON; 2008; 13(3):349-52. PubMed ID: 18979548
[TBL] [Abstract][Full Text] [Related]
12. Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: a Phase II Study of the Japanese Gynecologic Oncology Group.
Katsumata N; Fujiwara Y; Kamura T; Nakanishi T; Hatae M; Aoki D; Tanaka K; Tsuda H; Kamiura S; Takehara K; Sugiyama T; Kigawa J; Fujiwara K; Ochiai K; Ishida R; Inagaki M; Noda K
Jpn J Clin Oncol; 2008 Nov; 38(11):777-85. PubMed ID: 18927230
[TBL] [Abstract][Full Text] [Related]
13. CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan.
Gossner G; Coleman RL; Mutch DG; Horowitz NS; Rader JS; Gibb RK; Powell MA; Herzog TJ
Gynecol Oncol; 2006 Oct; 103(1):212-8. PubMed ID: 16677696
[TBL] [Abstract][Full Text] [Related]
14. A multicenter phase II study of pegylated liposomal doxorubicin and oxaliplatin in recurrent ovarian cancer.
Recchia F; Saggio G; Amiconi G; Di Blasio A; Cesta A; Candeloro G; Carta G; Necozione S; Mantovani G; Rea S
Gynecol Oncol; 2007 Jul; 106(1):164-9. PubMed ID: 17481704
[TBL] [Abstract][Full Text] [Related]
15. A study of pegylated liposomal Doxorubicin in platinum-refractory epithelial ovarian cancer.
Wilailak S; Linasmita V
Oncology; 2004; 67(3-4):183-6. PubMed ID: 15557776
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
Rose PG; Smrekar M; Haba P; Fusco N; Rodriguez M
Am J Clin Oncol; 2008 Oct; 31(5):476-80. PubMed ID: 18838885
[TBL] [Abstract][Full Text] [Related]
17. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer.
Rose PG
Oncologist; 2005 Mar; 10(3):205-14. PubMed ID: 15793224
[TBL] [Abstract][Full Text] [Related]
18. Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients.
Coleman RL; Gordon A; Barter J; Sun S; Rackoff W; Herzog TJ
Oncologist; 2007 Jan; 12(1):72-8. PubMed ID: 17227902
[TBL] [Abstract][Full Text] [Related]
19. Skin problems associated with pegylated liposomal doxorubicin-more than palmoplantar erythrodysesthesia syndrome.
Mangana J; Zipser MC; Conrad C; Oberholzer PA; Cozzio A; Knuth A; French LE; Dummer R
Eur J Dermatol; 2008; 18(5):566-70. PubMed ID: 18693162
[TBL] [Abstract][Full Text] [Related]
20. Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients.
Ko EM; Lippmann Q; Caron WP; Zamboni W; Gehrig PA
Gynecol Oncol; 2013 Dec; 131(3):683-8. PubMed ID: 24096112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
